CHITOSAN-BASED NANOCARRIERS FOR CONTROLLED DELIVERY OF TREOSULFAN IN LEUKEMIA THERAPY | ||
| Bulletin of Pharmaceutical Sciences Assiut University | ||
| Articles in Press, Accepted Manuscript, Available Online from 07 November 2025 | ||
| Document Type: Original Article | ||
| DOI: 10.21608/bfsa.2025.432477.2827 | ||
| Authors | ||
| Paravastu Venkata Kamala Kumari* 1; Rama Devi Korni2; Sai Srivastav Mylavarapu3 | ||
| 1Vignan Institute of Pharmaceutical Technology, Department of Pharmaceutics, Duvvada, Visakhapatnam | ||
| 2Department of Pharmaceutical Technology, Raghu College of Pharmacy, Visakhapatnam, Andhra Pradesh, India | ||
| 3Student, Regulatory Affairs, Northeastern University, Boston,MA. | ||
| Abstract | ||
| Treosulfan, a key chemotherapeutic for chronic myelogenous leukemia (CML) is a structural analogue of busulfan distinguished by the presence of two hydroxyl groups, which improve its solubility. Also known as dihydroxybusulfan, it functions as a cytostatic alkylating agent and is approved for use in advanced ovarian cancer therapy. In order to enhance the physicochemical features and sustained drug release of treosulfan loaded Chitosan Nanoparticles for possible biological applications. Ionic gelation was used to create nine formulations with different chitosan and tripolyphosphate (TPP) concentrations. With a mean particle size of 172 ± 8 nm, a zeta potential of 4 ± 1.5 mV, good drug entrapment efficiency, and sustained release over 24 hours, formulation F4 demonstrated the most desirable features. The successful production and structural integrity of F4 were validated by Atomic Force Microscopy (AFM) and Differential Scanning Calorimetry (DSC). Over the course of a day, in vitro experiments revealed that F4 released roughly 90% of the pharmacological payload. The physicochemical parameters and release kinetics of the formulations were shown to be strongly correlated by statistical analysis. F4 was found to be the most viable option for providing insights into improving formulation characteristics for improved therapeutic efficacy, developing nanoparticle-based drug delivery systems, and facilitating targeted drug delivery in cancer therapy. | ||
| Keywords | ||
| Chitosan nanoparticles; Nanocarriers; Ionic gelation; Chronic myelogenous leukemia (CML); Atomic force microscopy | ||
|
Statistics Article View: 4 |
||
